- Trials with a EudraCT protocol (31)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
31 result(s) found for: Malabsorption Syndromes.
Displaying page 1 of 2.
EudraCT Number: 2014-001941-25 | Sponsor Protocol Number: 2014-002 | Start Date*: 2014-12-16 | |||||||||||||||||||||
Sponsor Name:Rigshospitalet 2121 | |||||||||||||||||||||||
Full Title: Pilot Study with Treatment of Short Bowel Syndrome Patients with dipeptidyl-peptidase 4 inhibitor, Sitagliptin (Januvia®) | |||||||||||||||||||||||
Medical condition: Short Bowel Syndrome with intestinal failure (SBS IF) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002624-28 | Sponsor Protocol Number: FIT-EU-04 | Start Date*: 2015-09-24 |
Sponsor Name:Nutrinia Ltd. | ||
Full Title: A Multi-center, Double-blind, Randomized Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Gastrointestinal Maturation in Preterm Infants. | ||
Medical condition: Gastrointestinal Maturation in Preterm Infants. | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) BE (Completed) NL (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) DE (Prematurely Ended) BG (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-000181-60 | Sponsor Protocol Number: GIFT-02 | Start Date*: 2017-07-07 | |||||||||||||||||||||
Sponsor Name:Nutrinia Ltd. | |||||||||||||||||||||||
Full Title: A Multi-Center, Randomized, Double-Blind, Three-Arm, Parallel-Group trial to assess the efficacy and safety of NTRA-9620 in infants with Short Bowel Syndrome (SBS) following surgical resection. | |||||||||||||||||||||||
Medical condition: Short Bowel syndrome | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-004890-29 | Sponsor Protocol Number: FIT-PIV | Start Date*: 2023-03-09 | |||||||||||
Sponsor Name:Elgan Pharma Ltd | |||||||||||||
Full Title: A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants | |||||||||||||
Medical condition: Gastro-intestinal malabsorption due to gastro-intestinal immaturity in preterm infants. | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) ES (Ongoing) SE (Ongoing) NL (Ongoing) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006193-15 | Sponsor Protocol Number: CL0600-020 | Start Date*: 2009-06-25 | |||||||||||
Sponsor Name:NPS Pharmaceuticals, Inc. | |||||||||||||
Full Title: A 24-Week Study of the Efficacy and Safety of Teduglutide in Subjects with Parenteral Nutrition-Dependent Short Bowel Syndrome | |||||||||||||
Medical condition: Short Bowel Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) ES (Completed) FR (Completed) IT (Completed) GB (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001202-32 | Sponsor Protocol Number: TA799-007 | Start Date*: 2020-11-02 | |||||||||||
Sponsor Name:VectivBio AG | |||||||||||||
Full Title: A multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of apraglutide in adult subjects with short bowel syndrome and intestinal failure (SBS-IF) | |||||||||||||
Medical condition: short bowel syndrome and intestinal failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) FR (Completed) NO (Completed) BE (Completed) HU (Completed) PL (Completed) SE (Completed) DK (Completed) IT (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011679-65 | Sponsor Protocol Number: CL0600-021 | Start Date*: 2010-03-26 | |||||||||||
Sponsor Name:NPS Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Long Term, Open Label Study with Teduglutide for Subjects with Parenteral Nutrition Dependent Short Bowel Syndrome | |||||||||||||
Medical condition: Short Bowel Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) GB (Completed) DK (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-004195-42 | Sponsor Protocol Number: FIT-05 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Elgan Pharma Ltd | |||||||||||||
Full Title: A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Basket Study to Assess the Safety of ELGN-2112 in Populations of Interest | |||||||||||||
Medical condition: Gastro-intestinal malabsorption due to gastro-intestinal immaturity in preterm infants. | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) SE (Ongoing) ES (Ongoing) NL (Ongoing) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005502-25 | Sponsor Protocol Number: ZP1848-20110 | Start Date*: 2021-04-11 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: A 104-Week, Multicenter, Single-Arm, Long-Term, Phase 3 Extension Trial Investigating the Safety and Efficacy of Glepaglutide in Adult Patients with Short Bowel Syndrome (SBS) Completing the EASE S... | |||||||||||||
Medical condition: Short bowel syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Ongoing) BE (Ongoing) DE (Ongoing) DK (Ongoing) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004797-18 | Sponsor Protocol Number: | Start Date*: 2017-06-26 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Pilot study of the GLP-1 agonist, Liraglutide, on decreasing parenteral support requirements in short bowel patients. | |||||||||||||
Medical condition: Intestinal failure with an underlying aetiology of short bowel | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005513-41 | Sponsor Protocol Number: TA799-012 | Start Date*: 2021-04-19 | |||||||||||
Sponsor Name:VectivBio AG | |||||||||||||
Full Title: An open-label extension trial to evaluate the long-term safety of apraglutide in short bowel syndrome | |||||||||||||
Medical condition: short bowel syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) CZ (Ongoing) DE (Ongoing) FR (Ongoing) ES (Ongoing) IT (Ongoing) HU (Ongoing) DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002252-27 | Sponsor Protocol Number: TED-C14-006 | Start Date*: 2016-09-19 | |||||||||||
Sponsor Name:NPS Pharmaceuticals, Inc. | |||||||||||||
Full Title: A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age with Short Bowel Syndrome who are Dependent ... | |||||||||||||
Medical condition: Short Bowel Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) FI (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000825-35 | Sponsor Protocol Number: U1111-1167-2731 | Start Date*: 2015-08-27 | |||||||||||
Sponsor Name:Rigshospitalet Blegdamsvej | |||||||||||||
Full Title: The effect of the glucagon-like peptide-1 analogue, liraglutide (Victoza®), on jejunostomy output and intestinal absorption in short bowel syndrome patients, a double-blind cross-over study | |||||||||||||
Medical condition: Short bowel syndrome (SBS) is a clinical situation with reduced absorptive mucosal surface due to extensive surgical resection. SBS leads to increased intestinal losses of fluids and electrolytes; ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002826-38 | Sponsor Protocol Number: ZP1848-15073 | Start Date*: 2016-01-28 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: A phase 2 trial testing ZP1848 in patients with SBS | |||||||||||||
Medical condition: Short Bowel Syndrome (SBS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000863-17 | Sponsor Protocol Number: SHP633-303 | Start Date*: 2017-03-28 | |||||||||||
Sponsor Name:Shire Human Genetic Therapies, Inc. | |||||||||||||
Full Title: A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Subjects with Short Bowel Syndrome Who Completed TED-C13-003 Original PIP P/238/2010 | |||||||||||||
Medical condition: short bowel syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001405-32 | Sponsor Protocol Number: IMIS2017-02 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Institut des Maladies Génétiques - Imagine | |||||||||||||
Full Title: A Monocentric Single-arm study to characterize the long-term safety, efficacy, and pharmacodynamic of GLP-2 analog (Revestive®) in the management of short bowel syndrome pediatric patients on home-... | |||||||||||||
Medical condition: Short Bowel Syndrom | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004419-32 | Sponsor Protocol Number: PMS-2018-002 | Start Date*: 2019-10-03 | ||||||||||||||||
Sponsor Name:Pharmascience Inc. | ||||||||||||||||||
Full Title: A Phase IIa, Proof of Concept, Randomized, Double-Blind, Dose-Finding, Cross-Over Study of the Efficacy, Safety and Tolerability of a New Enteric-Coated Cholestyramine Capsule in Adult Short Bowel ... | ||||||||||||||||||
Medical condition: Bile-acid induced diarrhea in adult patients with Short Bowel Syndrome (SBS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005194-27 | Sponsor Protocol Number: ZP1848-20060 | Start Date*: 2021-06-30 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: A Single-Center Phase 3b Trial Investigating the Long-term Effect on Intestinal Absorption, Nutritional Status and Long-Term Safety of treatment with Glepaglutide in Patients with Short Bowel Syndr... | |||||||||||||
Medical condition: Short bowel syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000176-11 | Sponsor Protocol Number: HM-GLP2-201 | Start Date*: 2021-12-20 | |||||||||||
Sponsor Name:Hanmi Pharmaceutical Co., Ltd. | |||||||||||||
Full Title: A Multicenter, Proof-of-concept, Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15912 in Adult Subjects with Short Bowel Syndrome-associated Intesti... | |||||||||||||
Medical condition: Short Bowel Syndrome-associated Intestinal Failure (SBS-IF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) PL (Ongoing) BE (Ongoing) DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004394-14 | Sponsor Protocol Number: ZP1848-17111 | Start Date*: 2018-10-19 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: A Phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of glepaglutide in patients with short bowel syndrome (SBS) | |||||||||||||
Medical condition: Short bowel syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) DK (Completed) PL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.